Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

"Diabodies": small bivalent and bispecific antibody fragments.

Philipp Holliger, Teresa Di Prospero, Greg Winter · Proceedings of the National Academy of Sciences · 1993 · 875 citations · Full text

Pharmacy, Biochemistry, Immunology +17

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

G. Riethmüller, E Holz, Günter Schlimok et al. · Journal of Clinical Oncology · 1998 · 523 citations

Medicine, Immunology, Oncology +15

Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy

Holger N. Lode, Rong Xiang, Torsten Dreier et al. · Blood · 1998 · 178 citations · Full text

Life Sciences, Immunology, Oncology +16

Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody

Frank Hartmann, Christoph Renner, Wolfram Jung et al. · Blood · 1997 · 147 citations · Full text

Life Sciences, Immunology, Oncology +13